TAVR: Boston Scientific ’ s Acurate Neo, Edwards ’ Sapien 3 show similar results at 30 days

Outcomes from transcatheter aortic valve replacement procedures with both Boston Scientific‘s (NYSE:BSX) Acurate Neo and Edwards Lifesciences‘ (NYSE:EW) Sapien 3 have been found to be similar at 30 days, according to a new study reported by Healio. Results from the trial were published in the journal JACC: Cardiovascular Interventions, according to the report. The study explored the use of both Edwards’ balloon-expandable valve and Boston Scientific’s self-expanding valve in a total of 933 patients undergoing TAVR procedures. The study analyzed 622 patients treated with Edwards Sapien 3 and 311 individuals treated with the Acurate Neo and found comparable rates of in-hospital complications of 2.4% and 1.9%, respectively, according to Healio. Rates of major vascular complications were found to be 8.5% and 10.3% while life threatening bleeding was reported to be 3.7% and 4.2%, respectively. Device failure rates were also comparable between the two valves, with the Sapien 3 at 9.6% while the Acurate Neo had a reported rate of 10.9%. Differences between the 2 valves included rates of paravalvular leakage, with the Acurate Neo associated with a 4.8% rate versus a lower 1.8% rate with the Sapien 3, while the Acurate Neo was associated with fewer gradients of at least 20 mm Hg at 3.2% versus 6.9% and permanent pacemaker implants at 9.9% versus 15.5%, according to Healio. No significant differences were reported in 30-day mortality or in an early safety compo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Boston Scientific Edwards Lifesciences Source Type: news